PBPH Portfolio Building Block World Pharma and Biotech Index ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 29.83 | Day Range | 29.30 – 29.68 |
| 52-Week Range | 24.18 – 29.90 | Volume | 93.33K |
| Avg Volume | 122.81K | AUM | $933.1M (Aug 27, 2026) |
| Expense Ratio | 0.13% | Yield (TTM) | 0.08% |
| NAV | 29.67 | Premium/Discount | -1.14% indicative |
| Inception | Nov 23, 2025 | Holdings | — |
| Issuer | Portfolio Building Block ETFs | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 88635A204 | ISIN | US88635A2042 |
| Management | Passive / index-tracking (per issuer description) | ||
About this ETF
The Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) is designed to give investors specific exposure to the worldwide pharmaceutical and biotechnology sectors. These are recognized as some of the most rapidly evolving and research-intensive fields within healthcare. The ETF's objective is to emulate the returns of the BITA Global Pharma and Biotech Select Index, which tracks businesses operating in developed markets that generate a significant portion of their earnings from the invention, progression, and sale of treatments for human health.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +8.78% | +16.71% | +9.91% | +18.01% | — | — | — | — | +18.76% |
| Total return | +8.80% | +16.73% | +9.93% | +18.03% | — | — | — | — | +18.87% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.13% | Annual cost of a $10,000 investment | $13.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 25, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 56 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ELI LILLY & CO | LLY.TO | 15.32% | 128.62K | $161.5M |
| 2 | JOHNSON & JOHNSON | JNJ | 9.39% | 366.31K | $99.0M |
| 3 | ABBVIE INC | ABBV | 6.76% | 269.06K | $71.3M |
| 4 | MERCK & CO. INC. | MRK | 5.44% | 376.12K | $57.4M |
| 5 | AMGEN INC | AMGN | 4.88% | 117.04K | $51.4M |
| 6 | ROCHE HOLDING AG | — | 4.69% | 105.34K | $49.4M |
| 7 | NOVARTIS AG-REG | NVS | 4.20% | 278.06K | $44.2M |
| 8 | GILEAD SCIENCES INC | GILD | 3.90% | 281.69K | $41.2M |
| 9 | ASTRAZENECA PLC | AZN.L | 3.52% | 222.82K | $37.2M |
| 10 | PFIZER INC | PFE.BA | 3.44% | 1.29M | $36.3M |
| 11 | NOVO NORDISK A/S-B | — | 3.22% | 723.35K | $34.0M |
| 12 | VERTEX PHARMACEUTICALS INC | VRTX | 2.99% | 57.43K | $31.5M |
| 13 | BRISTOL-MYERS SQUIBB CO | BMY | 2.94% | 462.96K | $31.0M |
| 14 | SANOFI | SNY | 2.15% | 246.35K | $22.7M |
| 15 | GSK PLC | — | 2.10% | 845.13K | $22.1M |
| 16 | REGENERON PHARMACEUTICALS | REGN | 1.80% | 22.74K | $19.0M |
| 17 | CSL LTD | CSLLY | 1.43% | 124.94K | $15.1M |
| 18 | ARGENX SE | ARGX.BR | 1.41% | 14.07K | $14.8M |
| 19 | TAKEDA PHARMACEUTICAL CO LTD | 4502.T | 1.21% | 351.15K | $12.7M |
| 20 | BAYER AG-REG | BAYN.DE | 1.19% | 222.84K | $12.5M |
| 21 | MODERNA INC | MRNA | 1.10% | 79.86K | $11.6M |
| 22 | NATERA INC | NTRA | 0.97% | 30.75K | $10.2M |
| 23 | TEVA PHARMACEUTICAL IND LTD | TEVA.TA | 0.92% | 262.52K | $9.7M |
| 24 | SANDOZ GROUP AG | SDZNY | 0.81% | 92.73K | $8.5M |
| 25 | REVOLUTION MEDICINES INC | RVMD | 0.80% | 40.13K | $8.4M |
Click a ticker to see every ETF that owns it.
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.08% | Paid (last 12 months) | $0.0230 |
| Frequency | Irregular | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 24, 2025 | Last payment | $0.0230 (Dec 26, 2025) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 24, 2025 | Dec 24, 2025 | Dec 26, 2025 | $0.0230 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
Liquidity
| Volume today | 93.33K | Average volume | 122.81K |
| AUM | $933.1M | Premium/Discount | -1.14% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $933.1M → $933.1M |
| 1 Week | $469.7K | +0.05% | $933.1M → $933.1M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for PBPH
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.